Luye Pharma's "Goserelin Microspheres" Phase 3 Clinical Endpoint Reached

Text|Pharmaceutical Mission Hills

On September 6, Luye Pharmaceutical Group announced that its self-developed Goserelin Acetate Sustained Release Microspheres for Injection (LY01005) has completed a phase 3 clinical study for the treatment of prostate cancer in China and reached the preset end point

Androgen deprivation therapy (ADT) is an important systemic treatment for prostate cancer, and it plays an important "cornerstone" role in the treatment of various stages of prostate cancer

LY01005 is an innovative preparation independently developed based on Luye Pharma's innovative microsphere technology platform.

This time, reaching the preset endpoint is a randomized, open, positive drug-controlled Phase 3 clinical study, which aims to evaluate the effectiveness and safety of continuous intramuscular injection of LY01005 in the treatment of prostate cancer patients

Phase 3 clinical study results show that: LY01005 is injected intramuscularly at a dose of 3.

In addition to the field of prostate cancer treatment, LY01005's phase 3 clinical study for the treatment of breast cancer in China is also underway

Public information shows that Luye Pharma has formed a rich product portfolio in the field of microsphere technology: In addition to LY01005, Recinto has been approved in China for the treatment of schizophrenia; Palme is used for the treatment of schizophrenia and schizoaffective disorder.

source:

[1] Phase III clinical trials have reached the preset end point, and Luye Pharma is expected to launch the world's only goserelin microsphere preparation.